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Sudden cardiac deathAbstract A 17-year-old male patient with Gaucher disease was presented to our institution com-
plaining of rapid irregular palpitations. Echocardiography showed the presence of critical aortic
stenosis due to Gaucher disease.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Gaucher disease is a lysosome storage disease that leads to
accumulation of glycolipids in the cells and can be treated by
enzyme replacement therapy.1 Patients usually present with
hepatosplenomegaly, anemia, thrombocytopenia, bleeding ten-
dency, bone pain, osteopenia, pathologic fractures, growth
retardation, neurological manifestations and rarely cardiac
affection.2
2. Case report
A 17-year-old male patient, unemployed and single, has been
diagnosed as having Gaucher disease in 2003 when he was pre-
sented with growth retardation. The patient had hep-
atosplenomegaly, anemia and thrombocytopenia. A bone
marrow biopsy revealed Gaucher cells and a reduced gluco-
cerebrosidase activity was detected in peripheral leukocytes.
Hence, enzyme replacement therapy (recombinant glucocere-
brosidases) was given once every two weeks. The patient
reported that after therapy he became of average height andweight within two years. In 2011, the patient started manifest-
ing poor performance in school that led to school dropout in
2013. In addition, he complained of a head thrusting move-
ment since 2011 that was diagnosed as oculomotor nerve
apraxia.
The patient was presented to our facility in 9/2013 com-
plaining of exertional, irregular recurrent palpitations that ter-
minate spontaneously within 30 min by rest. He denied any
other cardiac symptoms including dyspnea, orthopnea, parox-
ysmal nocturnal dyspnea, chest pain nor syncope. Upon pre-
sentation, his blood pressure was 100/70 mmHg, heart rate
90 bpm and peripheral pulses well felt. Cardiac examination
revealed an ejection systolic murmur heard over aortic area
and a pansystolic murmur heard over the mitral area. Abdom-
inal examination revealed hepatosplenomegaly.
The electrocardiogram showed normal sinus rhythm with
left ventricular hypertrophy and strain pattern. The laboratory
workup was unremarkable except for microcytic hypochromic
anemia with hemoglobin: 7.7 g/dl, platelets: 59,000/Ul and the
chest X-ray was unremarkable.
Echocardiography revealed left ventricular hypertrophy
with a good systolic function (Ejection fraction: 70%)
(Fig. 1). The aortic valve was heavily calcific leading to critical
stenosis with a peak systolic velocity of 6 m/s, aortic valve area
0.5 cm2, mean systolic gradient 88 mmHg and mild aortic
Figure 1 M-mode across the left ventricular cavity showing a good systolic function and left ventricular hypertrophy.
Figure 2 Parasternal short view showing a heavily calcific aortic
valve.
Figure 3 Continuous Doppler wave across the aortic valve
showing critical aortic stenosis and mild aortic regurgitation.
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echodense walls. The aortic annulus, bisinus, Sinotubular
and ascending aorta measured were 16 mm, 20 mm, 17 mm
and 19 mm respectively (Figs. 4 and 5). The aortic calcifica-
tions were extending to the aortomitral intervalvular fibrosa
and to the anterior mitral valve leaflet, and focal calcifications
were visualized at the attachment of the posterior leaflet to the
lateral mitral annulus (Figs. 5 and 6). Both leaflets showed
mild restriction of mobility and the subvalvular involvement
was mild. All of the previous findings led to moderate regurgi-
tation and mild stenosis (Mitral valve area: 1.8 cm2 measured
by 2D planimetry) (Figs. 7 and 8). The pericardium appeared
to be echodense and thickened particularly at the posteriorbasal segment but there was no evidence of calcifications
(Fig. 6). In addition to the previous findings there was mild
pericardial effusion localized mainly at the posterior segment,
left atrial dilation, mild tricuspid regurgitation, and mild pul-
monary hypertension (predicted pulmonary artery systolic
pressure: 40 mmHg).
The patient was referred to the cardiothoracic surgery
department for the possibility of double valve replacement,
surgery was deferred as the patient was not complaining of
any symptoms of heart failure and the surgery was considered
to be of high risk due to thrombocytopenia plus the technical
difficulty in aortic valve replacement due to the small aortic
annulus. A follow-up was scheduled every three months.
Figure 4 A small aortic root with echodense walls.
Figure 5 Parasternal long axis view showing a heavily calcific
Aortic valve with calcification extending to the aortomitral
intervalvular fibrosa and into the anterior mitral valve leaflet, in
addition to a small left ventricular outflow tract measuring 16 mm.
Figure 6 Apical 3-chamber view showing a heavily calcific
Aortic valve with calcification extending to the aortomitral
intervalvular fibrosa and into the anterior mitral valve leaflet, in
addition to an echodense pericardium with maximal thickness at
the basal posterior segment with no evidence of calcification.
Figure 7 Mitral valve area was estimated to be 1.8 cm2 in 2D
planimetry.
Figure 8 Moderate mitral regurgitation.
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two months after discharge from our facility.
3. Discussion
Gaucher disease is an autosomal recessive disorder that results
from deficiency of the lysosomal enzyme glucocerebrosidase
that leads to accumulation of glucocerebroside and other gly-
colipids within the lysosomes of macrophages. The clinical
manifestations result from the accumulation of the lipid-
laden macrophages in the spleen, liver, bone marrow, bone,
and other tissues/organs including the heart.3 Diagnosis of
Gaucher disease is often made by bone marrow biopsy reveal-
ing Gaucher cells and confirmed by enzymatic analysis.4
Gaucher disease has an estimated incidence of 1 in 75,000
births worldwide and is classified into three types.3 Type I
is the most common type and is known by the absence of
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logical manifestations, which is characterized by early onset
typically in the first year after birth and has bad prognosis.5
Type III Gaucher disease is the chronic neuronopathic form
that has a later onset and less severe neurologic manifestations
in comparison with type II. Oculomotor apraxia is frequently
the only neurologic finding in type III as present in our patient.
Type III has an estimated incidence of 1 in 200,000 with well-
studied clusters in Northern Europe, Egypt and East Asia.6
Three forms of type III are still recognized, although there is
marked overlap and several authors recommend elimination
of the subclassification of type III. As for cardiac involvement
in Gaucher disease, it is rarely observed and was only reported
in type IIIC which is the rarest form of type III.2,7
Cardiovascular manifestations include pericardial, myocar-
dial, valvular, or great artery involvement. Patients may suffer
from diastolic heart failure due to a myocardial infiltrative
process leading to stiff ventricles.8
Gaucher disease may cause left sided valvular involvement
in the form of sclerosis and calcification leading to stenosis or
regurgitation. Young patients with severe valvular and sub-
valvular calcification must be evaluated with great caution as
sometimes severe calcification spreads to the coronary ostia,
the ascending aorta and even extending to the abdominal aorta
hence forming the so-called porcelain aorta.9
Patients diagnosed with Gaucher disease usually respond to
enzyme replacement therapy regarding anemia, thrombocy-
topenia, organomegaly and growth retardation;10 however, it
does not affect the neurological involvement as it does not
cross the blood brain barrier.11,12 As for the cardiac response
to therapy, Spada et al. reported a case that received three
years of enzyme replacement therapy resulting in improvement
in diastolic and systolic functions, decrease in previously
dilated dimensions and even reversal of deep T wave inversions
in the lateral leads of the electrocardiogram.13
In our case despite the patient received enzyme replacement
therapy for 11 years that improved his growth retardation, yet
such therapy did not affect the progression of his aortic valve
calcification and stenosis. Gaucher disease despite being rare it
should be ruled out in young patients presenting with severely
calcific valves especially in the presence of other signs and
symptoms suggestive of the disease.
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